

# M Ferrante

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7895203/publications.pdf>

Version: 2024-02-01

269  
papers

16,128  
citations

36303

51  
h-index

17592

121  
g-index

271  
all docs

271  
docs citations

271  
times ranked

17666  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 105-115.e14.	4.4	31
2	Population pharmacokineticâ€pharmacodynamic modelâ€based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 323-335.	2.4	9
3	Assessment of Endoscopic Disease Activity in Ulcerative Colitis: Is Simplicity the Ultimate Sophistication?. <i>Inflammatory Intestinal Diseases</i> , 2022, 7, 7-12.	1.9	16
4	Non-conventional Versus Conventional Strictureplasties for Crohn's Disease. A Systematic Review and Meta-analysis of Treatment Outcomes. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 319-330.	1.3	8
5	Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy. <i>Journal of Pediatrics</i> , 2022, 240, 150-157.e4.	1.8	10
6	Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for 1-year Endoscopic Remission in Moderate to Severe Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 616-624.	1.3	2
7	Inflammatory Bowel Disease-related Behaviours [IBD-Bx] Questionnaire: Development, Validation and Prospective Associations with Fatigue. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 581-590.	1.3	2
8	Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1135-1142.	1.9	5
9	Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 171-185.	8.1	57
10	P441 Adalimumab versus ustekinumab as first-line biological in a real-life cohort of moderate-to-severe Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i423-i424.	1.3	0
11	P401 Tofacitinib tissue exposure correlates with endoscopic outcome. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i394-i395.	1.3	2
12	OPO3 Standardized faecal microbiota transplantation with microbiome-guided donor selection in active UC patients: A randomized, placebo-controlled intervention study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i003-i004.	1.3	3
13	P603 INSPIRE: 6-month interim analysis from an observational post-marketing registry on the effectiveness and safety of darvadstrocel in patients with Crohn's disease and complex perianal fistulas. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i536-i537.	1.3	5
14	P544 Patients with moderate to severe Crohn's disease with and without prior biologic failure demonstrated improved clinical outcomes with risankizumab: Results from phase 3 induction and maintenance trials. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i491-i491.	1.3	1
15	P115 Implementation of a vaccination tool in the electronic patient health record significantly increases vaccination coverage. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i206-i207.	1.3	0
16	P004 Microbiota, not host origin drives ex vivo epithelial response in ulcerative colitis patients and non-IBD controls. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i136-i136.	1.3	1
17	DOP89 Infliximab and ustekinumab clearance during induction predicts post-induction endoscopic outcomes in patients with Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i131-i132.	1.3	0
18	P380 Early improvement of endoscopic outcomes with risankizumab is associated with reduced hospitalisation and surgery rates in patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i381-i382.	1.3	3

#	ARTICLE	IF	CITATIONS
19	P533 Predictors of sustained remission after infliximab de-escalation in patients with inflammatory bowel diseases. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i485-i486.	1.3	0
20	P073 Eosinophil depletion partially protects from colonic inflammation, but increases colonic collagen deposition in a DSS colitis model. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i177-i178.	1.3	0
21	Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies. <i>Journal of Crohn's and Colitis</i> , 2022, , .	1.3	4
22	DOP17 Evaluating segmental healing with the modified Mayo endoscopic score (MMES) has a clear additional value in predicting long-term outcome in patients with Ulcerative Colitis: Results from a prospective cohort study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i066-i067.	1.3	1
23	DOP73 A comparative efficacy and safety analysis of subcutaneous infliximab and vedolizumab in patients with Crohn's Disease and Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i116-i117.	1.3	0
24	P442 Real-world endoscopic and histologic outcomes are linked to ustekinumab exposure in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i424-i424.	1.3	3
25	P475 Profiling the use of Complementary Alternative Medicines among IBD patients. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i445-i446.	1.3	0
26	DOP81 Baseline whole-blood gene expression of TREM1 does not predict clinical or endoscopic outcomes following adalimumab treatment in patients with Ulcerative Colitis or Crohn's Disease in the SERENE studies. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i124-i125.	1.3	3
27	INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn's Disease Treated in the ADMIRE-CD Trial. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1737-1745.	1.9	19
28	P030 Distinct molecular profiles between idiopathic cryptoglandular and Crohn-related perianal fistulas. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i151-i151.	1.3	0
29	P529 Evolution of COVID19 serology in a real-life population of IMID patients. Results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID). <i>Journal of Crohn's and Colitis</i> , 2022, 16, i482-i483.	1.3	0
30	OP28 A randomized placebo controlled clinical trial with 5-hydroxytryptophan in patients with quiescent Inflammatory Bowel Disease and fatigue (Trp-IBD). <i>Journal of Crohn's and Colitis</i> , 2022, 16, i029-i032.	1.3	0
31	OP25 Patients with moderate to severe Crohn's Disease with and without prior biologic failure demonstrate improved endoscopic outcomes with risankizumab: Results from phase 3 induction and maintenance trials. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i027-i028.	1.3	3
32	DOP08 Transcriptional signatures of blood derived immune cells associated with disease location-based heterogeneity in IBD. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i058-i058.	1.3	0
33	P333 Precise and unbiased infliximab dosing in patients with inflammatory bowel diseases using a multi-model averaging approach. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i350-i351.	1.3	0
34	P576 Real-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn's disease: a Belgian multi-centric cohort study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i516-i517.	1.3	2
35	P447 Positioning of ustekinumab affects its effectiveness, drug persistence and serum exposure in Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i427-i428.	1.3	0
36	N01 Type of patient education impacts the willingness to switch from an IV to SC of a biological in patients with Inflammatory Bowel Disease: A multicentre, comparative study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i617-i618.	1.3	1

#	ARTICLE	IF	CITATIONS
37	P257 The clinical decision support tool has low performance in predicting outcome to ustekinumab in Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i298-i299.	1.3	0
38	Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results. <i>Gastroenterology</i> , 2022, 162, 1876-1890.	1.3	37
39	Severe Necrotizing Colitis in a 45-Year-Old Woman Without Cardiovascular History. <i>Gastroenterology</i> , 2022, 163, e1-e3.	1.3	0
40	Integrated analysis of microbe-host interactions in Crohn's disease reveals potential mechanisms of microbial proteins on host gene expression. <i>IScience</i> , 2022, 25, 103963.	4.1	7
41	Postoperative Crohn's Disease Recurrence: Time to Adapt Endoscopic Recurrence Scores to the Leading Surgical Techniques. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1201-1204.	4.4	13
42	Proctocolectomy and ileal pouch-anal anastomosis for the treatment of collagenous colitis. <i>Clinical Journal of Gastroenterology</i> , 2022, , 1.	0.8	2
43	Safety of sequential biological therapy in inflammatory bowel disease: results from a tertiary referral Centre. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, , .	3.7	1
44	Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 282-291.	3.7	5
45	Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1562-1570.	1.3	9
46	Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 1045-1059.	2.5	9
47	Microbiota, not host origin drives ex vivo intestinal epithelial responses. <i>Gut Microbes</i> , 2022, 14, .	9.8	8
48	Organoid-based Models to Study the Role of Host-microbiota Interactions in IBD. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1222-1235.	1.3	40
49	Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab Concentrations. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 988-993.	1.3	7
50	High-Dose Vitamin D Does Not Prevent Postoperative Recurrence of Crohn's Disease in a Randomized Placebo-Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1573-1582.e5.	4.4	20
51	Rates of Postoperative Recurrence of Crohn's Disease and Effects of Immunosuppressive and Biologic Therapies. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 713-720.e1.	4.4	31
52	Thiopurine monotherapy has a limited place in treatment of patients with mild-to-moderate Crohn's disease. <i>Gut</i> , 2021, 70, 1416-1418.	12.1	9
53	Intestinal Receptor of SARS-CoV-2 in Inflamed IBD Tissue Seems Downregulated by HNF4A in Ileum and Upregulated by Interferon Regulating Factors in Colon. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 485-498.	1.3	34
54	Positioning strictureplasty in the treatment of extensive Crohn's disease ileitis: a comparative study with ileocecal resection. <i>International Journal of Colorectal Disease</i> , 2021, 36, 791-799.	2.2	5

#	ARTICLE	IF	CITATIONS
55	Health Literacy and Quality of Life in Young Adults From The Belgian Crohn's Disease Registry Compared to Type 1 Diabetes Mellitus. <i>Frontiers in Pediatrics</i> , 2021, 9, 624416.	1.9	5
56	Effect of vedolizumab dose intensification on serum drug concentrations and regain of response in inflammatory bowel disease patients with secondary loss of response. <i>GastroHep</i> , 2021, 3, 63-71.	0.6	8
57	Monocyte TREM-1 Levels Associate With Anti-TNF Responsiveness in IBD Through Autophagy and Fcγ <sub>3</sub> -Receptor Signaling Pathways. <i>Frontiers in Immunology</i> , 2021, 12, 627535.	4.8	13
58	The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3776-3789.	2.4	8
59	P440 First results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID). <i>Journal of Crohn's and Colitis</i> , 2021, 15, S440-S440.	1.3	1
60	P280 Introduction of subcutaneous infliximab CT-P13 and vedolizumab in daily clinical practice: outstanding questions demonstrate the need for post-marketing studies. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S313-S314.	1.3	1
61	P062 Effects of exposure to steroids on the PredictSURE whole blood prognostic assay in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S168-S168.	1.3	4
62	P354 Early treatment versus active surveillance after ileocolic resection in Crohn's disease: a retrospective cohort study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S373-S374.	1.3	0
63	DOP22 Integrative -omic analysis reveals microbiota mediated molecular mechanisms influencing host mucosal gene expression in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S061-S062.	1.3	0
64	P618 Treatment outcomes of patients with Crohn's disease and complex perianal fistula in five European countries: the PREFACE retrospective study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S560-S560.	1.3	0
65	OP14 Extracellular RNAs as liquid biopsy non-invasive biomarker in IBD. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S014-S015.	1.3	0
66	P497 The value of endoscopic healing index monitoring for guiding infliximab dosing in patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S481-S483.	1.3	0
67	P285 A retrospective observational study on the effectiveness and safety of vedolizumab with or without budesonide induction therapy among patients with moderate-to-severe Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S317-S319.	1.3	0
68	P304 Rational infliximab induction dosing to achieve long-term deep remission in children with Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S332-S333.	1.3	0
69	P405 Development and validation of a rapid immunoassay for monitoring of ustekinumab concentrations in Inflammatory Bowel Disease patients. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S412-S412.	1.3	0
70	P676 The small intestinal microbiome in Crohn's disease is characterised by increased luminal diversity and stable mucosa-associated communities. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S597-S598.	1.3	0
71	P309 Are results from VARSITY applicable to real world? Adalimumab versus vedolizumab as first line biological in moderate-to-severe IBD. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S336-S337.	1.3	0
72	DOP08 Serum proteomics predict endoscopic remission in patients with Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S046-S047.	1.3	0

#	ARTICLE	IF	CITATIONS
73	P465 One year endoscopic and histologic outcomes to tofacitinib therapy in refractory ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S456-S457.	1.3	0
74	P307 Modelling of the relationship between ustekinumab exposure, faecal calprotectin and endoscopic outcomes in patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S335-S336.	1.3	0
75	P027 Epithelial cells of patients with ulcerative colitis do not show an increased sensitivity after microbiota stimulation compared to non-IBD controls. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S142-S143.	1.3	0
76	P311 Intensive dried blood spot sampling shows a higher drug exposure throughout the first 24 weeks of therapy in ustekinumab-treated Crohn's disease patients achieving endoscopic remission. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S338-S339.	1.3	0
77	Chronic Antibiotic-Refractory Pouchitis: Management Challenges. <i>Clinical and Experimental Gastroenterology</i> , 2021, Volume 14, 277-290.	2.3	3
78	Monitoring established Crohn's disease with pan-intestinal video capsule endoscopy in Europe: clinician consultation using the nominal group technique. <i>Current Medical Research and Opinion</i> , 2021, 37, 1547-1554.	1.9	3
79	Long-term clinical outcome after thiopurine discontinuation in elderly IBD patients. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 1323-1327.	1.5	2
80	Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis. <i>Pharmaceutics</i> , 2021, 13, 1623.	4.5	4
81	Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study. <i>United European Gastroenterology Journal</i> , 2021, 9, 1136-1147.	3.8	24
82	Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 54-61.	1.6	9
83	Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1455-1466.	3.1	10
84	Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 628-634.	1.9	9
85	Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2020, 158, 537-549.e10.	1.3	130
86	Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1142-1151.e10.	4.4	50
87	Long-term outcome of immunomodulator use in pediatric patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2020, 52, 164-172.	0.9	11
88	Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 332-341.	1.3	27
89	Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 129-138.	3.7	87
90	Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density. <i>Gut</i> , 2020, 69, 1778-1786.	12.1	79



#	ARTICLE	IF	CITATIONS
91	Update on the Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding. <i>Digestion</i> , 2020, 101, 27-42.	2.3	27
92	Efficacy of JAK inhibitors in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S737-S745.	1.3	12
93	Belgian IBD Research Group [BIRD] Position Statement 2019 on the Use of Adalimumab Biosimilars in Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 680-685.	1.3	11
94	Successful Infliximab Treatment is Associated With Reversal of Clotting Abnormalities in Inflammatory Bowel Disease Patients. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 819-825.	2.2	9
95	P219 Disease-specific avoidance is a predictor for fatigue in inflammatory bowel disease patients. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S250-S252.	1.3	0
96	P389 Post induction infliximab trough levels predict long-term endoscopic remission in paediatric patients with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S362-S363.	1.3	0
97	P391 Side-to-side stricturoplasty and its modification over the ileocecal valve for extensive Crohn's ileitis: single-centre long-term outcome. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S365-S366.	1.3	0
98	P421 Prognostic and therapeutic long-term outcome of patients with ulcerative proctitis: analysis from a large referral centre cohort study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S383-S384.	1.3	0
99	P464 Vedolizumab concentrations in colonic mucosal tissue of ulcerative colitis patients inversely correlate with the severity of inflammation. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S411-S412.	1.3	1
100	P508 Safety and efficacy of combining biological therapies together or with small molecules in patients with inflammatory bowel disease: A retrospective multicentre national observational case series study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S440-S442.	1.3	1
101	P801 Treatment patterns of complex perianal fistula in Crohn's disease in five European countries: the PREFACE study, a retrospective chart review. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S628-S628.	1.3	5
102	P546 Ileal ulcer size significantly impacts the ability to achieve endoscopic remission: a post-hoc analysis from the SONIC trial. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S465-S465.	1.3	0
103	2020 international consensus on ANCA testing beyond systemic vasculitis. <i>Autoimmunity Reviews</i> , 2020, 19, 102618.	5.8	79
104	Worries and concerns of inflammatory bowel disease (IBD) patients in Belgium – a validation of the Dutch rating form. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 1427-1432.	1.5	3
105	Molecular Changes in the Non-Inflamed Terminal Ileum of Patients with Ulcerative Colitis. <i>Cells</i> , 2020, 9, 1793.	4.1	4
106	Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial. <i>American Journal of Gastroenterology</i> , 2020, 115, 1236-1245.	0.4	23
107	The prevention and management of Crohn's disease postoperative recurrence: results from the Y-ECCO/ClinCom 2019 Survey. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1062-1066.	1.6	8
108	Gastroenterologists' preference and risk perception on the use of immunomodulators and biological therapies in elderly patients with ulcerative colitis: an international survey. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 976-983.	1.6	9

#	ARTICLE	IF	CITATIONS
109	P542 The effect of age on infliximab pharmacokinetics in patients with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S462-S463.	1.3	0
110	Invasive nocardiosis, disseminated varicella zoster reactivation, and pneumocystis jiroveci pneumonia associated with tofacitinib and concomitant systemic corticosteroid use in ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2294-2297.	2.8	8
111	Ulcerative colitis. <i>Nature Reviews Disease Primers</i> , 2020, 6, 74.	30.5	678
112	Ex Vivo Mimicking of Inflammation in Organoids Derived From Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2020, 159, 1564-1567.	1.3	36
113	Software Tools for Model-Informed Precision Dosing: How Well Do They Satisfy the Needs?. <i>Frontiers in Pharmacology</i> , 2020, 11, 620.	3.5	62
114	Fibrogenesis in chronic murine colitis is independent of innate lymphoid cells. <i>Immunity, Inflammation and Disease</i> , 2020, 8, 393-407.	2.7	4
115	Development and feasibility of a telemonitoring tool with full integration in the electronic medical record: a proof of concept study for patients with inflammatory bowel disease in remission on biological therapy. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 287-293.	1.5	7
116	Evaluating an easy sampling method using dried blood spots to determine vedolizumab concentrations. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 185, 113224.	2.8	12
117	Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological era "getting nearer?". <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 737-738.	3.7	4
118	OP20 The gut microbiota during biological therapy for inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S016-S018.	1.3	0
119	Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. <i>Gastroenterology</i> , 2020, 159, 139-147.	1.3	126
120	P061 The molecular landscape of perianal fistula in Crohn's disease: opportunities for new therapeutic approaches. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S165-S165.	1.3	3
121	Long-term outcomes of patients with ulcerative proctitis: Analysis from a large referral centre cohort. <i>United European Gastroenterology Journal</i> , 2020, 8, 933-941.	3.8	18
122	P601 Development and validation of dried blood spot sampling as a tool to identify the best time point to measure predictive ustekinumab serum concentrations in patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S502-S502.	1.3	2
123	OP01 Higher vs. standard adalimumab maintenance regimens in patients with moderately to severely active ulcerative colitis: Results from the SERENE-UC maintenance study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S001-S001.	1.3	17
124	OP37 Fibrogenesis in chronic DSS colitis is driven by an innate lymphoid cell-independent innate immune response. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S038-S039.	1.3	0
125	Short- and Long-term Outcomes Following Side-to-side Strictureplasty and its Modification Over the Ileocaecal Valve for Extensive Crohn's Ileitis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1378-1384.	1.3	8
126	OP27 Long-term safety and efficacy of risankizumab treatment in patients with Crohn's disease: Final results from the Phase 2 open-label extension study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S024-S025.	1.3	10



#	ARTICLE	IF	CITATIONS
127	DOP31 Serum protein markers for early and differential IBD diagnosis validated by machine learning approaches. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S070-S070.	1.3	0
128	Quality of care in an inflammatory bowel disease clinical trial center : a prospective study evaluating patients' satisfaction. <i>Acta Gastro-Enterologica Belgica</i> , 2020, 83, 25-31.	1.0	1
129	Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 156-162.	1.9	24
130	TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn's disease patients?. <i>Gut</i> , 2019, 68, 1531-1533.	12.1	42
131	A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2019, 26, 570-580.	1.9	10
132	Fibrogenesis in Chronic DSS Colitis is Not Influenced by Neutralisation of Regulatory T Cells, of Major T Helper Cytokines or Absence of IL-13. <i>Scientific Reports</i> , 2019, 9, 10064.	3.3	10
133	P697 <i>Pneumocystis jirovecii</i> pneumonia in IBD patients treated with immunomodulator(s). <i>Journal of Crohn's and Colitis</i> , 2019, 13, S468-S469.	1.3	1
134	P032 Hepatocyte growth factor and MET in ulcerative colitis, novel drug targets impairing neutrophil recruitment?. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S102-S102.	1.3	0
135	DOP26 Biological therapy increases NCR+ ILC3 levels in IBD patients. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S040-S040.	1.3	2
136	OP38 Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with moderately-to-severely active ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S026-S027.	1.3	5
137	DOP37 Vedolizumab-induced endoscopic remission in anti-TNF exposed and anti-TNF naïve IBD patients: a large single-centre experience. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S047-S048.	1.3	1
138	DOP46 Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S054-S054.	1.3	0
139	DOP52 Reduction in inflammatory biomarkers in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S059-S060.	1.3	0
140	Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease. <i>EBioMedicine</i> , 2019, 40, 733-742.	6.1	119
141	Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 864-872.	1.3	83
142	Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 572-581.	3.7	52
143	Cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn's disease. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 607-616.	3.1	14
144	New biologics and small molecules in inflammatory bowel disease: an update. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481985320.	3.2	82

#	ARTICLE	IF	CITATIONS
145	Short Health Scale: a valid and reliable measure of quality of life in Dutch speaking patients with inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 592-596.	1.5	3
146	P253 The impact of storage time and freeze-thaw cycles on faecal calprotectin concentration in inflammatory bowel disease patients and controls. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S223-S223.	1.3	0
147	P542 Efficacy and safety of biological therapies in chronic antibiotic-refractory pouchitis: a retrospective single-centre experience. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S385-S385.	1.3	1
148	Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1248-1256.	1.3	32
149	Butyrate Does Not Protect Against Inflammation-induced Loss of Epithelial Barrier Function and Cytokine Production in Primary Cell Monolayers From Patients With Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1351-1361.	1.3	48
150	P827 Up-regulation of IL17-related pathways in affected colon from ulcerative colitis compared with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S537-S538.	1.3	0
151	P589 A population pharmacokinetic model to improve mucosal healing upon golimumab induction therapy in patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S409-S410.	1.3	1
152	Editorial: biomarker predictors of non-response to TNF antagonists – the quest continues. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1091-1092.	3.7	0
153	P408 Switching from infliximab originator to a biosimilar does not affect efficacy, pharmacokinetics and immunogenicity in paediatric patients with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S313-S314.	1.3	0
154	P385 TREM1, the first anti-TNF specific biomarker guiding therapeutic decision. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S300-S300.	1.3	0
155	P836 The predictive role of gut microbiota in treatment response to vedolizumab and ustekinumab in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S542-S542.	1.3	1
156	THU0627...VACCINATIONS IN PATIENTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES: STILL ROOM FOR IMPROVEMENT. , 2019, , .		0
157	P290 Compliance to vaccination guidelines in patients with immune-mediated inflammatory diseases: a cross-sectional, single-centre study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S244-S245.	1.3	0
158	Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience. <i>United European Gastroenterology Journal</i> , 2019, 7, 1215-1225.	3.8	32
159	Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2019, 68, 847-853.	1.8	36
160	Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1175-1181.	2.8	25
161	Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information. <i>AAPS Journal</i> , 2019, 21, 10.	4.4	13
162	No Change in Determining Crohn's Disease Recurrence or Need for Endoscopic or Surgical Intervention With Modification of the Rutgeerts Scoring System. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1643-1645.	4.4	53

#	ARTICLE	IF	CITATIONS
163	Optimising infliximab induction dosing for patients with ulcerative colitis. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 782-795.	2.4	27
164	Gene and Mirna Regulatory Networks During Different Stages of Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 916-930.	1.3	41
165	Edematous Colitis of an Unknown Cause, Diagnosis by Pattern Recognition. <i>Gastroenterology</i> , 2019, 156, e12-e13.	1.3	3
166	Impact of endoscopy system, high definition, and virtual chromoendoscopy in daily routine colonoscopy: a randomized trial. <i>Endoscopy</i> , 2019, 51, 237-243.	1.8	23
167	Efficacy and safety of radiofrequency ablation of Barrett's esophagus in the absence of reimbursement: a multicenter prospective Belgian registry. <i>Endoscopy</i> , 2019, 51, 317-325.	1.8	11
168	Vedolizumab in Refractory Microscopic Colitis: An International Case Series. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 337-340.	1.3	37
169	Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 12-18.	1.3	47
170	Anti-TNF and Pouch Surgery for Ulcerative Colitis: The Ones who Blame for More Complications?. <i>Current Drug Targets</i> , 2019, 20, 1349-1355.	2.1	2
171	AUTOMATED REAL TIME ENDOSCOPIC SCORING BASED ON MACHINE LEARNING IN ULCERATIVE COLITIS: RED DENSITY RELIABILITY AND RESPONSIVENESS STUDY. <i>Endoscopy</i> , 2019, 51, .	1.8	0
172	Ulcerative colitis treatment : an insight into daily clinical practice. <i>Acta Gastro-Enterologica Belgica</i> , 2019, 82, 365-372.	1.0	0
173	Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1099-1105.	1.9	22
174	Unusual yellow scaly colonic mucosal appearance: Tangier disease. <i>Gastrointestinal Endoscopy</i> , 2018, 88, 193-195.	1.0	1
175	Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1276-1283.e1.	4.4	39
176	Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018, 154, 1334-1342.e4.	1.3	331
177	Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 402-407.	1.3	66
178	New treatment options for inflammatory bowel diseases. <i>Journal of Gastroenterology</i> , 2018, 53, 585-590.	5.1	142
179	Effect of vedolizumab (anti- $\alpha$ 4 $\beta$ 7-integrin) therapy on histological healing and mucosal gene expression in patients with UC. <i>Gut</i> , 2018, 67, 43-52.	12.1	137
180	Outcome of restorative proctocolectomy with an ileoanal pouch for ulcerative colitis: effect of changes in clinical practice. <i>Colorectal Disease</i> , 2018, 20, O30-O38.	1.4	16

#	ARTICLE	IF	CITATIONS
181	Risk Stratification for Surgery in Structuring Ileal Crohn's Disease: The BACARDI Risk Model. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 32-38.	1.3	33
182	Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists. <i>United European Gastroenterology Journal</i> , 2018, 6, 439-445.	3.8	13
183	Anti-Înfliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 346-355.	3.7	41
184	OP007 Detection of mucosal healing with a serum marker panel in adalimumab-treated patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S005-S005.	1.3	2
185	P035 Serum markers predict outcome to ustekinumab in patients with refractory Crohn's disease and provide insights in the mechanism of action. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S110-S110.	1.3	1
186	P330 A prospective trial to evaluate the feasibility of a mobile app in patients with inflammatory bowel disease under maintenance therapy. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S269-S269.	1.3	0
187	Effects of Epithelial IL-13R <sup>1±2</sup> Expression in Inflammatory Bowel Disease. <i>Frontiers in Immunology</i> , 2018, 9, 2983.	4.8	17
188	P042 Decreased leukocyte trafficking may contribute to vedolizumab refractory disease after anti-TNF exposure in patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S113-S113.	1.3	0
189	When IBD is not IBD. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1085-1088.	1.5	7
190	P704 Ustekinumab induces limited mucosal healing after 6 months in a real-life, prospective cohort of patients with refractory Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S467-S467.	1.3	1
191	Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease—A Multicenter Retrospective European Study. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2442-2451.	1.9	56
192	Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1937-1946.e8.	4.4	113
193	P045 Dried blood spot sampling can facilitate therapeutic drug monitoring of vedolizumab therapy. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S114-S115.	1.3	0
194	Failure of MMP-9 Antagonists in IBD: Demonstrating the Importance of Molecular Biology and Well-Controlled Early Phase Studies. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1011-1013.	1.3	9
195	Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 731-739.	3.7	62
196	Prognostic value of histological activity in patients with ulcerative colitis in deep remission: A prospective multicenter study. <i>United European Gastroenterology Journal</i> , 2018, 6, 765-772.	3.8	53
197	DOP001 Effectiveness and safety of vedolizumab in anti-TNF naïve patients with inflammatory bowel disease: a multicentre retrospective European Crohn's and Colitis Organisation study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S029-S030.	1.3	2
198	Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD). <i>Acta Gastro-Enterologica Belgica</i> , 2018, 81, 49-53.	1.0	1

#	ARTICLE	IF	CITATIONS
199	A Simplified Geboes Score for Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jjw154.	1.3	44
200	Specific members of the predominant gut microbiota predict pouchitis following colectomy and IPAA in UC. <i>Gut</i> , 2017, 66, 79-88.	12.1	114
201	Epithelial organoid cultures from patients with ulcerative colitis and Crohn's disease: a truly long-term model to study the molecular basis for inflammatory bowel disease?. <i>Gut</i> , 2017, 66, 2193-2195.	12.1	43
202	Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease – a nested case-control study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 923-932.	3.7	28
203	Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. <i>Lancet, The</i> , 2017, 389, 1699-1709.	13.7	364
204	Development of organoids from mouse and human endometrium showing endometrial epithelium physiology and long-term expandability. <i>Development (Cambridge)</i> , 2017, 144, 1775-1786.	2.5	228
205	Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1086-1092.	1.5	32
206	Inhibition of gelatinase B/MMP-9 does not attenuate colitis in murine models of inflammatory bowel disease. <i>Nature Communications</i> , 2017, 8, 15384.	12.8	40
207	A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 809-821.	2.4	32
208	Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn's Disease and Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1085-1089.	1.3	58
209	ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease – An Update. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 26-34.	1.3	194
210	Human intestinal epithelium in a dish: Current models for research into gastrointestinal pathophysiology. <i>United European Gastroenterology Journal</i> , 2017, 5, 1073-1081.	3.8	35
211	Pit pattern analysis with high-definition chromoendoscopy and narrow-band imaging for optical diagnosis of dysplasia in patients with ulcerative colitis. <i>Gastrointestinal Endoscopy</i> , 2017, 86, 1100-1106.e1.	1.0	42
212	Genetic and Transcriptomic Bases of Intestinal Epithelial Barrier Dysfunction in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1718-1729.	1.9	156
213	Short- and medium-term outcomes following primary ileocaecal resection for Crohn's disease in two specialist centres. <i>British Journal of Surgery</i> , 2017, 104, 1713-1722.	0.3	91
214	DOP029 Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post-hoc analysis of the taxit trial. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S44-S45.	1.3	0
215	Management of Postoperative Crohn's Disease: Missing Pieces of the Puzzle. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1291-1292.	1.3	4
216	Perioperative Use of Vedolizumab is not Associated with Postoperative Infectious Complications in Patients with Ulcerative Colitis Undergoing Colectomy. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1353-1361.	1.3	56

#	ARTICLE	IF	CITATIONS
217	Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease. Expert Opinion on Biological Therapy, 2017, 17, 31-47.	3.1	29
218	Submucosal Plexitis as a Predictive Factor for Postoperative Endoscopic Recurrence in Patients with Crohn's Disease Undergoing a Resection with Ileocolonic Anastomosis: Results from a Prospective Single-centre Study. Journal of Crohn's and Colitis, 2017, 11, 212-220.	1.3	42
219	Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis. Journal of Crohn's and Colitis, 2017, 11, 53-59.	1.3	57
220	Validation of a Drug-Resistant Anti-Adalimumab Antibody Assay to Monitor Immunogenicity in the Presence of High Concentrations of Adalimumab. AAPS Journal, 2017, 19, 468-474.	4.4	16
221	DOP028 Antibodies towards vedolizumab appear from week 2 onwards and disappear upon treatment. Journal of Crohn's and Colitis, 2017, 11, S44-S44.	1.3	0
222	P382 A panel of serum markers for early detection of endoscopic healing with infliximab in patients with ulcerative colitis. Journal of Crohn's and Colitis, 2017, 11, S271-S272.	1.3	0
223	P438 Adalimumab dose escalation and de-escalation in ulcerative colitis: incidence and predictors of success. A real life Belgian cohort study. Journal of Crohn's and Colitis, 2017, 11, S299-S299.	1.3	1
224	P035 TNF-driven pathways are increased at baseline in Crohn's disease patients not responding to infliximab. Journal of Crohn's and Colitis, 2017, 11, S96-S97.	1.3	0
225	P686 Application of dried blood spots for pharmacokinetic profiling of golimumab-treated patients with ulcerative colitis. Journal of Crohn's and Colitis, 2017, 11, S430-S431.	1.3	0
226	" The effectiveness of intravenous iron for iron deficiency anemia in gastrointestinal cancer patients: a retrospective study". Annals of Gastroenterology, 2017, 30, 654-663.	0.6	10
227	Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation. Clinical and Translational Gastroenterology, 2016, 7, e206.	2.5	52
228	Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab. Journal of Crohn's and Colitis, 2016, 10, 1015-1023.	1.3	66
229	Sarcoidosis-Like Lesions: Another Paradoxical Reaction to Anti-TNF Therapy?. Journal of Crohn's and Colitis, 2016, 11, jiw155.	1.3	35
230	Letter: smoking as a modifiable risk factor for a complicated course in Crohn's disease. Authors' reply. Alimentary Pharmacology and Therapeutics, 2016, 43, 441-441.	3.7	0
231	Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet, The, 2016, 388, 1281-1290.	13.7	771
232	Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience. Alimentary Pharmacology and Therapeutics, 2016, 44, 673-683.	3.7	42
233	Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease. Annals of Internal Medicine, 2016, 164, 10.	3.9	111
234	Genetic Deletion of Tissue Inhibitor of Metalloproteinase-1/TIMP-1 Alters Inflammation and Attenuates Fibrosis in Dextran Sodium Sulphate-induced Murine Models of Colitis. Journal of Crohn's and Colitis, 2016, 10, 1336-1350.	1.3	34



#	ARTICLE	IF	CITATIONS
235	Variability in Golimumab Exposure: A "Real-Life" Observational Study in Active Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 575-581.	1.3	71
236	Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 543-549.	4.4	154
237	Modified Side-To-Side Isoperistaltic Strictureplasty over the Ileocaecal Valve: An Alternative to Ileocaecal Resection in Extensive Terminal Ileal Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 437-442.	1.3	37
238	Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial. <i>Gut</i> , 2016, 65, 1126-1131.	12.1	82
239	Strong Upregulation of AIM2 and IFI16 Inflammasomes in the Mucosa of Patients with Active Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2673-2682.	1.9	94
240	Smoking behaviour and knowledge of the health effects of smoking in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1294-1302.	3.7	26
241	Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 441-451.	3.7	148
242	Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2015, 148, 1320-1329.e3.	1.3	745
243	Systematic versus Endoscopy-driven Treatment with Azathioprine to Prevent Postoperative Ileal Crohn's Disease Recurrence. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 617-624.	1.3	44
244	Long-Term Outcome of Patients With Crohn's Disease Who Discontinued Infliximab Therapy Upon Clinical Remission. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1103-1110.	4.4	76
245	Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 514-521.e4.	4.4	116
246	The Modified Mayo Endoscopic Score (MMES): A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis Patients. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 846-852.	1.3	108
247	Postoperative Inflammatory Response in Crohn's Patients: A Comparative Study. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 1127-1131.	1.3	18
248	Immunogenicity to infliximab is associated with HLA-DRB1. <i>Gut</i> , 2015, 64, 1344-1345.	12.1	57
249	Serum Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Marker for Mucosal Healing in Patients with Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 1079-1087.	1.3	39
250	A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 531-538.	4.4	158
251	Drug safety evaluation of certolizumab pegol. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 255-266.	2.4	15
252	Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1324-1332.	3.7	64

#	ARTICLE	IF	CITATIONS
253	A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis. <i>Gut</i> , 2014, 63, 1275-1283.	12.1	1,353
254	Integrated miRNA and mRNA Expression Profiling in Inflamed Colon of Patients with Ulcerative Colitis. <i>PLoS ONE</i> , 2014, 9, e116117.	2.5	73
255	European evidence based consensus for endoscopy in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 982-1018.	1.3	679
256	Recent advances: personalised use of current Crohn's disease therapeutic options. <i>Gut</i> , 2013, 62, 1511-1515.	12.1	30
257	Validation of Endoscopic Activity Scores in Patients With Crohn's Disease Based on a Post Hoc Analysis of Data From SONIC. <i>Gastroenterology</i> , 2013, 145, 978-986.e5.	1.3	155
258	Certolizumab pegol in the treatment of Crohn's disease. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 595-605.	3.1	5
259	Unique Gene Expression and MR T2 Relaxometry Patterns Define Chronic Murine Dextran Sodium Sulphate Colitis as a Model for Connective Tissue Changes in Human Crohn's Disease. <i>PLoS ONE</i> , 2013, 8, e68876.	2.5	42
260	Medical Therapy and Mucosal Healing. <i>Current Drug Targets</i> , 2012, 13, 1294-1299.	2.1	8
261	Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: Results from an international survey and discussion programme. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 116-131.	1.3	18
262	Long-term Expansion of Epithelial Organoids From Human Colon, Adenoma, Adenocarcinoma, and Barrett's Epithelium. <i>Gastroenterology</i> , 2011, 141, 1762-1772.	1.3	2,835
263	Second primary malignancies in patients with a gastrointestinal neuroendocrine tumour: a case report and review of the literature. <i>Acta Gastro-Enterologica Belgica</i> , 2010, 73, 397-402.	1.0	0
264	Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. <i>Gut</i> , 2009, 58, 492-500.	12.1	479
265	Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. <i>Gut</i> , 2009, 58, 501-508.	12.1	391
266	Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1062-1070.	1.9	225
267	Reply to Dr. Caprilli et al.'s letter. <i>Journal of Crohn's and Colitis</i> , 2009, 3, 45.	1.3	0
268	Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease. <i>Gastroenterology</i> , 2009, 137, 1628-1640.	1.3	460
269	Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. <i>Gut</i> , 2009, 58, 1612-1619.	12.1	346